Equities

Adimmune Corp

4142:TAI

Adimmune Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)24.10
  • Today's Change-0.25 / -1.03%
  • Shares traded699.35k
  • 1 Year change-25.73%
  • Beta--
Data delayed at least 20 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast

The one analyst offering a 12 month price target expects Adimmune Corp share price to rise to 35.00 in the next year from the last price of 24.10.
High45.2%35.00
Med45.2%35.00
Low45.2%35.00

Earnings history & estimates in TWD

Earnings forecasts are not available for Adimmune Corp. On Aug 13, 2024, Adimmune Corp reported 2nd quarter 2024 losses of -- per share.
Adimmune Corp reported annual 2023 losses of -1.52 per share on Mar 13, 2024.
Average growth rate+241.65%
More ▼

Revenue history & estimates in TWD

Revenue forecasts are not available for Adimmune Corporation.
Average growth rate+518.30%
Adimmune Corporation had revenues for the full year 2023 of 1.79bn. This was 20.72% below the prior year's results.
Average growth rate+12.02%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.